307 related articles for article (PubMed ID: 37744063)
1. Advancement of regulating cellular signaling pathways in NSCLC target therapy via nanodrug.
Li W; Li M; Huang Q; He X; Shen C; Hou X; Xue F; Deng Z; Luo Y
Front Chem; 2023; 11():1251986. PubMed ID: 37744063
[TBL] [Abstract][Full Text] [Related]
2. Biodegradable Nanoparticles Mediated Co-delivery of Erlotinib (ELTN) and Fedratinib (FDTN) Toward the Treatment of ELTN-Resistant Non-small Cell Lung Cancer (NSCLC) via Suppression of the JAK2/STAT3 Signaling Pathway.
Chen D; Zhang F; Wang J; He H; Duan S; Zhu R; Chen C; Yin L; Chen Y
Front Pharmacol; 2018; 9():1214. PubMed ID: 30483119
[No Abstract] [Full Text] [Related]
3. miRNAs in anti-cancer drug resistance of non-small cell lung cancer: Recent advances and future potential.
Yan H; Tang S; Tang S; Zhang J; Guo H; Qin C; Hu H; Zhong C; Yang L; Zhu Y; Zhou H
Front Pharmacol; 2022; 13():949566. PubMed ID: 36386184
[TBL] [Abstract][Full Text] [Related]
4. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y
Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
[TBL] [Abstract][Full Text] [Related]
5. An Activatable Nano-Prodrug for Treating Tyrosine-Kinase-Inhibitor-Resistant Non-Small Cell Lung Cancer and for Optoacoustic and Fluorescent Imaging.
Xie X; Zhan C; Wang J; Zeng F; Wu S
Small; 2020 Sep; 16(38):e2003451. PubMed ID: 32815304
[TBL] [Abstract][Full Text] [Related]
6. Investigating regulated signaling pathways in therapeutic targeting of non-small cell lung carcinoma.
Alam M; Hasan GM; Eldin SM; Adnan M; Riaz MB; Islam A; Khan I; Hassan MI
Biomed Pharmacother; 2023 May; 161():114452. PubMed ID: 36878052
[TBL] [Abstract][Full Text] [Related]
7. Strategy to enhance lung cancer treatment by five essential elements: inhalation delivery, nanotechnology, tumor-receptor targeting, chemo- and gene therapy.
Garbuzenko OB; Kuzmov A; Taratula O; Pine SR; Minko T
Theranostics; 2019; 9(26):8362-8376. PubMed ID: 31754402
[TBL] [Abstract][Full Text] [Related]
8. Efficacy analysis of targeted nanodrug for non-small cell lung cancer therapy.
Li T; Zhou T; Liu Y; Wang J; Yu Z
Front Bioeng Biotechnol; 2022; 10():1068699. PubMed ID: 36425650
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in non-small cell lung cancer targeted therapy; an update review.
Araghi M; Mannani R; Heidarnejad Maleki A; Hamidi A; Rostami S; Safa SH; Faramarzi F; Khorasani S; Alimohammadi M; Tahmasebi S; Akhavan-Sigari R
Cancer Cell Int; 2023 Aug; 23(1):162. PubMed ID: 37568193
[TBL] [Abstract][Full Text] [Related]
10. A pharmacological exploration of targeted drug therapy in non-small cell lung cancer.
Jayan AP; Anandu KR; Madhu K; Saiprabha VN
Med Oncol; 2022 Jul; 39(10):147. PubMed ID: 35834033
[TBL] [Abstract][Full Text] [Related]
11. Molecular target therapeutics of EGF-TKI and downstream signaling pathways in non-small cell lung cancers.
Liu CY; Lin HF; Lai WY; Lin YY; Lin TW; Yang YP; Tsai FT; Wang CL; Luo YH; Chen YM; Hsu PK; Kai LJ; Kiat AOH; Chien Y; Chiou SH; Wang CY
J Chin Med Assoc; 2022 Apr; 85(4):409-413. PubMed ID: 35383703
[TBL] [Abstract][Full Text] [Related]
12. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
13. Marked synergy by vertical inhibition of EGFR signaling in NSCLC spheroids shows SOS1 is a therapeutic target in EGFR-mutated cancer.
Theard PL; Sheffels E; Sealover NE; Linke AJ; Pratico DJ; Kortum RL
Elife; 2020 Sep; 9():. PubMed ID: 32897190
[TBL] [Abstract][Full Text] [Related]
14. Non-small cell lung cancer combination therapy: Hyaluronic acid modified, epidermal growth factor receptor targeted, pH sensitive lipid-polymer hybrid nanoparticles for the delivery of erlotinib plus bevacizumab.
Pang J; Xing H; Sun Y; Feng S; Wang S
Biomed Pharmacother; 2020 May; 125():109861. PubMed ID: 32070872
[TBL] [Abstract][Full Text] [Related]
15. The emerging role of circular RNAs in drug resistance of non-small cell lung cancer.
Yan T; Tian X; Liu F; Liu Q; Sheng Q; Wu J; Jiang S
Front Oncol; 2022; 12():1003230. PubMed ID: 36303840
[TBL] [Abstract][Full Text] [Related]
16. Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer.
Wang Z; Xing Y; Li B; Li X; Liu B; Wang Y
Mol Biomed; 2022 Dec; 3(1):42. PubMed ID: 36508072
[TBL] [Abstract][Full Text] [Related]
17. Screening common signaling pathways associated with drug resistance in non-small cell lung cancer via gene expression profile analysis.
Sun T; Zhao Q; Zhang C; Cao L; Song M; Maimela NR; Liu S; Wang J; Gao Q; Qin G; Wang L; Zhang Y
Cancer Med; 2019 Jun; 8(6):3059-3071. PubMed ID: 31025554
[TBL] [Abstract][Full Text] [Related]
18. Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance.
Wu J; Lin Z
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499382
[TBL] [Abstract][Full Text] [Related]
19. MET genetic lesions in non-small-cell lung cancer: pharmacological and clinical implications.
Zorzetto M; Ferrari S; Saracino L; Inghilleri S; Stella GM
Transl Lung Cancer Res; 2012 Sep; 1(3):194-207. PubMed ID: 25806181
[TBL] [Abstract][Full Text] [Related]
20. Cancer genomics of lung cancer including malignant mesothelioma: A brief overview of current status and future prospects.
Jhanwar SC; Xu XL; Elahi AH; Abramson DH
Adv Biol Regul; 2020 Dec; 78():100723. PubMed ID: 32992231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
